FCPA/Anti-Corruption Compliance in Pharmaceutical Industry: A 2017 Update Live Webcast
True to its promise, the U.S. Securities and Exchange Commission (SEC) is going back to the pharma industry after a break for a number of years. Recently, following several other SEC resolutions in the life sciences sector, the SEC has announced its settlement with AstraZeneca PLC. The company’s Chinese and Russian subsidiaries were alleged to have violated the Foreign Corrupt Practices Act’s (FCPA) internal controls and recordkeeping requirements, resulting to AstraZeneca’s payment of $4,325,000 in profit disgorgement, $822,000 in prejudgment interest and $375,000 for civil penalty.
With this renewed focus on the industry and the increased international cooperation, pharmaceutical companies should ensure that a strong anti-corruption compliance program is in place.
In this two-hour LIVE Webcast, a panel of thought leaders and practitioners assembled by The Knowledge Group will discuss the significant FCPA updates and developments in 2016 for the Pharmaceutical Industry and will provide a comprehensive outlook for the year ahead. Speakers will also provide expert insights on the best compliance practices.
Key topics include:
FCPA/Anti-Corruption in Pharmaceutical Industry: Current Trends
Common Anti-Corruption Risks
Best Compliance Practices
Speakers:Glenn Pomerantz, Partner Global Foresics Practice, BDO ConsultingMary Bennett, Vice President Advisory Services, NAVEXJeffrey Antoon, Director of Internal Audit, Johnson & JohnsonGary Fair, Vice President of Corporate Internal Audit, Johnson & JohnsonJane Yoon, Of Counsel, Paul Hastings
Tuesday March 14, 201712:00 - 2:00pm ESTLive Webcast